Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

Original reporting
Published Nov 16, 2026, 11:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026 — source image
Decision brief

The 30-second read

$ABTNeutralMed
01

Why it matters

For ABT, the key trade is balancing accelerating PFA ablation adoption and new FDA/CE milestones against a stated near-term headwind from LAA order delays.

02

Market read

Company-specific regulatory approvals and launch timing for EP devices are actionable for positioning into Q4, but the LAA demand slowdown adds uncertainty to near-term earnings trajectory.

03

What to watch

The piece does not quantify how much LAA weakness offsets EP acceleration, so traders may need to monitor order cadence and reimbursement or competitive dynamics not discussed here.

Relevance 7/10Novelty 5/10Timing: ahead of Q4 launch milestones and near-term LAA order trend watch

Background

The article frames Abbott’s 2026 EP performance around Volt PFA adoption and a growing EP catheter portfolio, while flagging LAA demand softness after Amulet 360 CE Mark.

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott reports ABT Medical Devices EP sales growth and details FDA approval for its TactiFlex Duo PFA/RF catheter plus Volt launch expectations.

Expected impact

Likely modest upside bias as investors price in Volt/TactiFlex ramp, tempered by near-term LAA order softness.

Evidence & confidence

The article provides multiple company-specific catalysts (FDA approval, Japan launch timing, U.S. full-quarter contribution) alongside a concrete demand headwind (slower U.S. LAA orders after Amulet 360 CE Mark).

Market effects

Signals continued adoption of pulsed field ablation and expanding electrophysiology device portfolios, which can influence sentiment across cardiac ablation and device peers.

Highlights Japan as a potential tailwind for Volt adoption, suggesting regional diffusion dynamics for PFA technology.

Reinforces a broader medtech theme of electrophysiology procedure growth driven by new energy modalities, with Europe and U.S. adoption patterns in focus.

Counterpoint

The LAA slowdown tied to Amulet 360 CE Mark could dominate near-term results, making EP growth less supportive than it appears.

Key entities

  • Abbott Laboratories

    ABT Medical Devices segment, with EP growth drivers (Volt PFA, TactiFlex Duo FDA approval) and LAA headwind (Amulet 360 CE Mark order delays).

  • Volt pulsed field ablation catheter

    Abbott’s PFA catheter whose adoption accelerated after U.S. market release and is expected to launch in Japan in Q4.

  • TactiFlex Duo Ablation Catheter, Sensor Enabled

    FDA-approved catheter allowing PFA, RF, or combination use, with broader U.S. launch expected in Q4.

  • Amulet 360 LAA Occluder

    CE-marked LAA occluder; U.S. orders reportedly slowed after CE Mark approval as accounts delayed purchases.

Related articles

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

$ABTMedAI 8/10

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.